Polysaccharide-K augments docetaxel-induced tumor suppression and antitumor immune response in an immunocompetent murine model of human prostate cancer

International Journal of Oncology

Volumn 40, Issue 4, 2012, Pages 905-913

  Wenner, Cynthia A ^a   Martzen, Mark R ^a   Lu, Hailing ^c   Verneris, Michael R ^b   Wang, Hongbo ^b   Slaton, Joel W ^b  

^a BASTYR UNIVERSITY   (United States)

^b UNIVERSITY OF MINNESOTA   (United States)

^c UNIVERSITY OF WASHINGTON   (United States)

Author keywords

Apoptosis; Docetaxel; Natural killer cell; Polysaccharide K; Prostate cancer

Indexed keywords

DOCETAXEL; GAMMA INTERFERON; KRESTIN; MESSENGER RNA; TRANSCRIPTION FACTOR FOXP3;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER INHIBITION; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELL INFILTRATION; CONTROLLED STUDY; CYTOLYSIS; HUMAN; LEUKOCYTE COUNT; MOUSE; NATURAL KILLER CELL; NONHUMAN; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN EXPRESSION; REGULATORY T LYMPHOCYTE; TARGET CELL; TUMOR IMMUNITY; TUMOR VOLUME;

ANIMALS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; APOPTOSIS; CELL LINE, TUMOR; DRUG SYNERGISM; HUMANS; IMMUNOCOMPETENCE; IMMUNOHISTOCHEMISTRY; MALE; MICE; MICE, INBRED C57BL; PROSTATIC NEOPLASMS; PROTEOGLYCANS; TAXOIDS; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84863353628     PISSN: 10196439     EISSN: 17912423     Source Type: Journal    
DOI: 10.3892/ijo.2011.1292     Document Type: Article

References (45)

1. Ferlay J, Shin HR, Bray F, Forman D, Mathers C and Parkin DM: Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer 127: 2893-2917, 2010.
2. Lassi K and Dawson NA: Update on castrate-resistant prostate cancer: 2010. Curr Opin Oncol 22: 263-267, 2010.
3. Petrylak DP, Tangen CM, Hussain MH, et al: Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. N Engl J Med 351: 1513-1520, 2004. (Pubitemid 39315318)
4. Tannock IF, De Wit R, Berry WR, et al: Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med 351: 1502-1512, 2004. (Pubitemid 39315317)
5. Gueritte-Voegelein F, Guenard D, Lavelle F, Le Goff MT, Mangatal L and Potier P: Relationships between the structure of taxol analogues and their antimitotic activity. J Med Chem 34: 992-998, 1991.
6. Bissery MC, Guenard D, Gueritte-Voegelein F and Lavelle F: Experimental antitumor activity of taxotere (RP 56976, NSC 628503), a taxol analogue. Cancer Res 51: 4845-4852, 1991.
7. Mike S, Harrison C, Coles B, Staffurth J, Wilt TJ and Mason MD: Chemotherapy for hormone-refractory prostate cancer. Cochrane Database Syst Rev: CD005247, 2006.
8. Quartino AL, Friberg LE and Karlsson MO: A simultaneous analysis of the time-course of leukocytes and neutrophils following docetaxel administration using a semi-mechanistic myelosuppression model. Invest New Drugs: Dec 14, 2010 (E-pub ahead of print).
9. Kantoff PW, Higano CS, Shore ND, et al: Sipuleucel-T immunotherapy for castration-resistant prostate cancer. N Engl J Med 363: 411-422, 2010.
10. Rozkova D, Tiserova H, Fucikova J, et al: FOCUS on FOCIS: combined chemo-immunotherapy for the treatment of hormone-refractory metastatic prostate cancer. Clin Immunol 131: 1-10, 2009.
11. Fong L, Kwek SS, O'Brien S, et al: Potentiating endogenous antitumor immunity to prostate cancer through combination immunotherapy with CTLA4 blockade and GM-CSF. Cancer Res 69: 609-615, 2009.
12. Hodi FS, O'Day SJ, McDermott DF, et al: Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med 363: 711-723, 2010.
13. Small EJ, Tchekmedyian NS, Rini BI, Fong L, Lowy I and Allison JP: A pilot trial of CTLA-4 blockade with human anti-CTLA-4 in patients with hormone-refractory prostate cancer. Clin Cancer Res 13: 1810-1815, 2007. (Pubitemid 46952950)
14. Bristol-Myers Squibb. Phase 3 Study of Immunotherapy to Treat Advanced Prostate Cancer. In: ClinicalTrial.gov [Internet]. Bethesda (MD): National Library of Medicine (US), 2000- [cited 20110824]. Available from: http://clinicaltrials.gov/ct2/show/NCT01057810: NCT01057810.
15. Bristol-Myers Squibb. Study of Immunotherapy to Treat Advanced Prostate Cancer. In: ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US), 2000- [cited 20110824]. Available from: http://clinicaltrials. gov/ct2/show/NCT00861614: NCT00861614.
16. Kobayashi H, Matsunaga K and Oguchi Y: Antimetastatic effects of PSK (Krestin), a protein-bound polysaccharide obtained from basidiomycetes: an overview. Cancer Epidemiol Biomarkers Prev 4: 275-281, 1995.
17. Lu H, Yang Y, Gad E, et al: Polysaccharide krestin is a novel TLR2 agonist that mediates inhibition of tumor growth via stimulation of CD8 T cells and NK cells. Clin Cancer Res 17: 67-76, 2011.
18. Mickey DD, Bencuya PS and Foulkes K: Effects of the immunomodulator PSK on growth of human prostate adenocarcinoma in immunodeficient mice. Int J Immunopharmacol 11: 829-838, 1989. (Pubitemid 19252370)
19. Hayakawa K, Mitsuhashi N, Saito Y, et al: Effect of Krestin as adjuvant treatment following radical radiotherapy in non-small cell lung cancer patients. Cancer Detect Prev 21: 71-77, 1997. (Pubitemid 27307074)
20. Hayakawa K, Mitsuhashi N, Saito Y, et al: Effect of krestin (PSK) as adjuvant treatment on the prognosis after radical radiotherapy in patients with non-small cell lung cancer. Anticancer Res 13: 1815-1820, 1993.
21. Iino Y, Yokoe T, Maemura M, et al: Immunochemotherapies versus chemotherapy as adjuvant treatment after curative resection of operable breast cancer. Anticancer Res 15: 2907?-2911, 1995.
22. Oba K, Teramukai S, Kobayashi M, Matsui T, Kodera Y and Sakamoto J: Efficacy of adjuvant immunochemotherapy with polysaccharide K for patients with curative resections of gastric cancer. Cancer Immunol Immunother 56: 905-911, 2007. (Pubitemid 46729147)
23. Nakazato H, Koike A, Saji S, Ogawa N and Sakamoto J: Efficacy of immunochemotherapy as adjuvant treatment after curative resection of gastric cancer. Study Group of Immunochemotherapy with PSK for Gastric Cancer. Lancet 343: 1122-1126, 1994. (Pubitemid 24142032)
24. Sakamoto J, Morita S, Oba K, et al: Efficacy of adjuvant immunochemotherapy with polysaccharide K for patients with curatively resected colorectal cancer: a meta-analysis of centrally randomized controlled clinical trials. Cancer Immunol Immunother 55: 404-411, 2006. (Pubitemid 43076892)
25. Zhang H, Morisaki T, Nakahara C, et al: PSK-mediated NF-kappaB inhibition augments docetaxel-induced apoptosis in human pancreatic cancer cells NOR-P1. Oncogene 22: 2088-2096, 2003. (Pubitemid 36539559)
26. Kinoshita J, Fushida S, Harada S, et al: PSK enhances the efficacy of docetaxel in human gastric cancer cells through inhibition of nuclear factor-kappaB activation and survivin expression. Int J Oncol 36: 593-600, 2010.
27. Yamasaki A, Shoda M, Iijima H, et al: A protein-bound polysaccharide, PSK, enhances tumor suppression induced by docetaxel in a gastric cancer xenograft model. Anticancer Res 29: 843-850, 2009.
28. Vremec D and Shortman K: Dendritic cell subtypes in mouse lymphoid organs: cross-correlation of surface markers, changes with incubation, and differences among thymus, spleen, and lymph nodes. J Immunol 159: 565-573, 1997. (Pubitemid 127484204)
29. Katoh R, Takenoshita S, Shimizu Y, Tanaka S, Yajima Y and Nagamachi Y: Effects on host of modified PVP therapy combined with biological response modifiers in lung cancer. Oncol Rep 5: 103-107, 1998. (Pubitemid 28039827)
30. Castelo-Branco P, Passer BJ, Buhrman JS, et al: Oncolytic herpes simplex virus armed with xenogeneic homologue of prostatic acid phosphatase enhances antitumor efficacy in prostate cancer. Gene Ther 17: 805-810, 2010.
31. Dzojic H, Loskog A, Totterman TH and Essand M: Adenovirus-mediated CD40 ligand therapy induces tumor cell apoptosis and systemic immunity in the TRAMP-C2 mouse prostate cancer model. Prostate 66: 831-838, 2006.
32. Reddy KR, Guan Y, Qin G, Zhou Z and Jing N: Combined treatment targeting HIF-1alpha and Stat3 is a potent strategy for prostate cancer therapy. Prostate 71: 1796-1809, 2011.
33. Yi H, Yu X, Guo C, Manjili MH, Repasky EA and Wang XY: Adoptive cell therapy of prostate cancer using female mice-derived T cells that react with prostate antigens. Cancer Immunol Immunother 60: 349-360, 2011.
34. Kato M, Hirose K, Hakozaki M, et al: Induction of gene expression for immunomodulating cytokines in peripheral blood mononuclear cells in response to orally administered PSK, an immunomodulating protein-bound polysaccharide. Cancer Immunol Immunother 40: 152-156, 1995.
35. Ng TB: A review of research on the protein-bound polysaccharide (polysaccharopeptide, PSP) from the mushroom Coriolus versicolor (Basidiomycetes: Polyporaceae). Gen Pharmacol 30: 1-4, 1998.
36. Kodama N, Mizuno S, Nanba H and Saito N: Potential antitumor activity of a low-molecular-weight protein fraction from Grifola frondosa through enhancement of cytokine production. J Med Food 13: 20-30, 2010.
37. Masuda Y, Inoue M, Miyata A, Mizuno S and Nanba H: Maitake beta-glucan enhances therapeutic effect and reduces myelosupression and nephrotoxicity of cisplatin in mice. Int Immunopharmacol 9: 620-626, 2009.
38. Rubel R, Dalla Santa HS, Bonatto SJ, et al: Medicinal mushroom Ganoderma lucidum (Leyss: Fr) Karst. triggers immunomodulatory effects and reduces nitric oxide synthesis in mice. J Med Food 13: 142-148, 2010.
39. Si MS, Imagawa DK, Ji P, et al: Immunomodulatory effects of docetaxel on human lymphocytes. Invest New Drugs 21: 281-290, 2003. (Pubitemid 37486330)
40. Suzuki Y and Tokuda Y: [Docetaxel]. Gan to Kagaku Ryoho 28: 1363-1367, 2001.
41. Mason K, Staab A, Hunter N, et al: Enhancement of tumor radioresponse by docetaxel: involvement of immune system. Int J Oncol 18: 599-606, 2001.
42. Markasz L, Skribek H, Uhlin M, et al: Effect of frequently used chemotherapeutic drugs on cytotoxic activity of human cytotoxic T-lymphocytes. J Immunother 31: 283-293, 2008. (Pubitemid 351441005)
43. Ogden CL, Fryar CD, Carroll MD and Flegal KM: Mean body weight, height, and body mass index, United States 1960-2002. Adv Data pp1-17, 2004.
44. Hirono M, Yoshinaka K, Matsuki K, et al: [Surgical treatment of Borrmann type 4 (diffuse) gastric cancer]. Gan No Rinsho 30: 717-723, 1984.
45. Kidd PM: The use of mushroom glucans and proteoglycans in cancer treatment. Altern Med Rev 5: 4-27, 2000.